Hence, we investigated the novel hypothesis that cancer cells escape the pro-apoptotic effects of μM TMX by inhibiting c-Cbl activation via the redox/Fyn/c-Cbl (RFC) pathway, and that Cdc42 inhibition will enhance the utility of TMX as a potential treatment for ERα-negative cancer cells. Here, CDC42 is linked to cancer.